{"entity":{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","aka":["Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd."],"tldr":"Shanghai Fosun Pharmaceutical Industrial Development is a China-based pharmaceutical company running 5 late-stage cancer trials of FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood.","summary":"Shanghai Fosun Pharmaceutical Industrial Development, based in Shanghai, China, is a pharmaceutical company and part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. listed as 600196.SH; 02196.HK. Part of the Fosun Pharma group, a China-rooted global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical devices, diagnostics, healthcare services and pharmaceutical distribution. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood. The largest, NCT06569420 (Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC), plans to enrol 275 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.fosunpharma.com"},{"label":"ClinicalTrials.gov: trials led by Shanghai Fosun Pharmaceutical Industrial Development","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Fosun%20Pharmaceutical%20Industrial%20Development%20Co.%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06858618","nct06569420","nct04954001","nct07562581"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://www.fosunpharma.com","ticker":"600196.SH; 02196.HK","founded":1994,"stage":"public","investors":[],"funding":[]},"route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/"}],"trial":[{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/"},{"id":"nct06858618","kind":"trial","name":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","route":"/trials/nct06858618/"},{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/"},{"id":"nct04954001","kind":"trial","name":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","route":"/trials/nct04954001/"}]}}